Internal Medicine Alert – September 15, 2013
September 15, 2013
View Issues
-
Fluoroquinolones and the Risk of Acute Kidney Injury
Fluoroquinolones are commonly prescribed bactericidal agents with a wide spectrum of activity. In addition to the coverage against conventional gram-negative organisms, newer agents in this class have an expanded spectrum of activity against a variety of gram-positive and atypical organisms. -
MORES Power to You
This cross-sectional studys purpose was to validate the Male Osteoporosis Risk Estimation Score (MORES) in a primary care setting; it had been previously validated in the National Health and Nutrition Examination Survey (NHANES) III. -
Poor Sleep Quality May Predict Preclinical Alzheimer’s Disease
Insomnia is a common complaint among adults and it is well recognized that mental performance can be impaired by poor sleep. Both difficulty falling asleep and trouble staying asleep have been associated with poor cognitive function in cross-sectional elderly cohorts. -
Pharmacology Update: Dolutegravir Tablets (Tivicay®)
Dolutegravir, a once daily hiv-1 integrase strand transfer inhibitor (INSTI), has been approved by the FDA. -
Clinical Briefs By Louis Kuritzky
Our Newest Pharmacologic Class for Treatment of Diabetes: SGLT2 Inhibitors -
ECG Review - Mobitz I or Mobitz II AV Block?